Clinical Trials Directory

Trials / Completed

CompletedNCT00195507

Study Evaluating Etanercept in the Treatment of Subjects With Psoriasis

A Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etanercept in the Treatment of Subjects With Psoriasis

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
720 (actual)
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study will provide a direct comparison of 'continuous therapy' and 'intermittent therapy' with withdrawal and retreatment upon return of psoriasis.

Conditions

Interventions

TypeNameDescription
DRUGEtanercept

Timeline

Start date
2004-12-01
Completion
2007-02-01
First posted
2005-09-19
Last updated
2013-02-25
Results posted
2010-05-04

Locations

127 sites across 19 countries: Austria, Belgium, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Netherlands, Norway, Poland, Portugal, Spain, Sweden, Switzerland, Turkey (Türkiye), United Kingdom

Source: ClinicalTrials.gov record NCT00195507. Inclusion in this directory is not an endorsement.

Study Evaluating Etanercept in the Treatment of Subjects With Psoriasis (NCT00195507) · Clinical Trials Directory